Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference 02/13/17Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors 02/10/17
EventsLEERINK Partners 6th Annual Global Healthcare Conference02/15/17 2:30 p.m. ETView eventSeattle Genetics Business Update02/10/17 8:30 a.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|